Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Nanomedicine in Cancer Targeting and Therapy
share announcement

Special Issue "Nanomedicine in Cancer Targeting and Therapy"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 5333

Special Issue Editors

Prof. Dr. Stefano Leporatti

E-Mail Website
Guest Editor
CNR Nanotec-Istituto di Nanotecnologia, Via Monteroni, c/o Campus Ekotecne, 73100 Lecce, LE, Italy
Interests: nanomedicine; drug delivery; scanning force microscopy; cytomechanics; nanocarriers
Special Issues, Collections and Topics in MDPI journals
Dr. Ilaria Elena Palamà

E-Mail Website
Guest Editor
CNR Nanotec-Istituto di Nanotecnologia, Via Monteroni, c/o Campus Ekotecne, 73100 Lecce, Italy
Interests: drug delivery; gene delivery; leukemia cancer cells; nanomedicine; nanocarriers; nano-delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Background: Cancer is a deadly disease widespread all over the world, and many scientists as well as medical doctors are fighting it and devoting their efforts in order to find a personalized cure extendable to everyone.

Aim and Scope: In this respect, nanotechnology applied to medicine, so-called nanomedicine, has attracted a wealth of attention since its inception and has shown extremely high numbers of prospective and promising results, especially around tailored nanocarriers for targeted drug delivery.

History: Several types of nano-vectors and nanotools were developed in the past to better drive neoplastic drugs to reach specifically tumoral tissues and cells, allowing a reduction in side effects and bearing reduced administrated doses.

Cutting-Edge Research: Targeted cancer nanotechnology is a promising expandable area with possible and significant future improvements, allowing medical doctors to possess a new weapon in the universal war against cancer.

The Kind of Papers We Are Looking For: We are seeking research articles and review papers in the area of targeted drug delivery, aiming to shine a light over recent nanomedicine developments and provide future perspectives, envisaging new directions in the personalized treatment of cancer patients.

Prof. Dr. Stefano Leporatti
Dr. Ilaria Elena Palamà
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer nanotechnology
  • nanomedicine
  • nanocarriers
  • nano-delivery
  • target therapy
  • drug delivery
  • gene delivery
  • nano-theragnostic

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

2 pages, 184 KiB  
Editorial
Nanomedicine in Cancer Targeting and Therapy
by
Ilaria Elena Palamà
and
Stefano Leporatti
J. Pers. Med. 2022, 12(8), 1312; https://doi.org/10.3390/jpm12081312 - 13 Aug 2022
Viewed by 1032
Abstract
Currently, cancer represents a major cause of death in the world, despite all the progress made in developing new therapies [...] Full article
(This article belongs to the Special Issue Nanomedicine in Cancer Targeting and Therapy)

Research

Jump to: Editorial, Review

18 pages, 3407 KiB  
Article
Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl4-Induced Liver Fibrosis in Rats
by
Elisa Panzarini
,
Stefano Leporatti
,
Bernardetta Anna Tenuzzo
,
Alessandra Quarta
,
Nemany A. N. Hanafy
,
Gianluigi Giannelli
,
Camilla Moliterni
,
Diana Vardanyan
,
Carolina Sbarigia
,
Marco Fidaleo
,
Stefano Tacconi
and
Luciana Dini
J. Pers. Med. 2022, 12(11), 1812; https://doi.org/10.3390/jpm12111812 - 01 Nov 2022
Cited by 1 | Viewed by 1902
Abstract
Hepatic fibrosis (HF) is a major cause of liver-related disorders and together with cancer-associated fibroblasts can favor liver cancer development by modulating the tumor microenvironment. Advanced HF, characterized by an excess of extracellular matrix (ECM), is mediated by TGF- β1, that activates hepatic [...] Read more.
Hepatic fibrosis (HF) is a major cause of liver-related disorders and together with cancer-associated fibroblasts can favor liver cancer development by modulating the tumor microenvironment. Advanced HF, characterized by an excess of extracellular matrix (ECM), is mediated by TGF- β1, that activates hepatic stellate cells (HSCs) and fibroblasts. A TGF-β1 receptor inhibitor, LY2157299 or Galunisertib (GLY), has shown promising results against chronic liver progression in animal models, and we show that it can be further improved by enhancing GLYs bioavailability through encapsulation in polymeric polygalacturonic-polyacrylic acid nanomicelles (GLY-NMs). GLY-NMs reduced HF in an in vivo rat model of liver fibrosis induced by intraperitoneal injection of CCl4 as shown by the morphological, biochemical, and molecular biology parameters of normal and fibrotic livers. Moreover, GLY-NM was able to induce recovery from HF better than free GLY. Indeed, the encapsulated drug reduces collagen deposition, hepatic stellate cells (HSCs) activation, prevents fatty degeneration and restores the correct lobular architecture of the liver as well as normalizes the serum parameters and expression of the genes involved in the onset of HF. In summary, GLY-NM improved the pharmacological activity of the free TGF- β1 inhibitor in the in vivo HF treatment and thus is a candidate as a novel therapeutic strategy. Full article
(This article belongs to the Special Issue Nanomedicine in Cancer Targeting and Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

26 pages, 3518 KiB  
Review
Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives
by
Francesca Persano
and
Stefano Leporatti
J. Pers. Med. 2022, 12(10), 1736; https://doi.org/10.3390/jpm12101736 - 19 Oct 2022
Cited by 4 | Viewed by 1651
Abstract
To date, cancer continues to be one of the deadliest diseases. Current therapies are often ineffective, leading to the urgency to develop new therapeutic strategies to improve treatments. Conventional chemotherapeutics are characterized by a reduced therapeutic efficacy, as well as them being responsible [...] Read more.
To date, cancer continues to be one of the deadliest diseases. Current therapies are often ineffective, leading to the urgency to develop new therapeutic strategies to improve treatments. Conventional chemotherapeutics are characterized by a reduced therapeutic efficacy, as well as them being responsible for important undesirable side effects linked to their non-specific toxicity. In this context, natural nanomaterials such as clayey mineral nanostructures of various shapes (flat, tubular, spherical and fibrous) with adjustable physico-chemical and morphological characteristics are emerging as systems with extraordinary potential for the delivery of different therapeutic agents to tumor sites. Thanks to their submicron size, high specific surface area, high adsorption capacity, chemical inertia and multilayer organization of 0.7 to 1 nm-thick sheets, they have aroused considerable interest among the scientific community as nano systems that are highly biocompatible in cancer therapy. In oncology, the nano-clays usually studied are halloysite, bentonite, laponite, kaolinite, montmorillonite and sepiolite. These are multilayered minerals that can act as nanocarriers (with a drug load generally between 1 and 10% by weight) for improved stabilization, efficient transport and the sustained and controlled release of a wide variety of anticancer agents. In particular, halloysite, montmorillonite and kaolinite are used to improve the dissolution of therapeutic agents and to delay and/or direct their release. In this review, we will examine and expose to the scientific community the extraordinary potential of nano-clays as unique crystalline systems in the treatment of cancer. Full article
(This article belongs to the Special Issue Nanomedicine in Cancer Targeting and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop